Latest news with #CD19
Yahoo
30-05-2025
- Business
- Yahoo
Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas
First-in-human trial is designed to determine recommended dose of IKS03, a CD19-directed antibody drug conjugate, for the subsequent dose-expansion IKS03 is Iksuda's second asset to begin clinical testing NEWCASTLE, England, May 30, 2025--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of dosing of its first patient with IKS03, a CD19-directed ADC, in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma. This first-in-human study ( will evaluate the safety, tolerability, preliminary antineoplastic activity, pharmacokinetics and pharmacodynamics of increasing dose levels of IKS03, and determine the recommended dose for dose-expansion. Efficacy will be further evaluated in disease-specific expansion cohorts. The study is currently enrolling patients across clinical sites in Italy, Spain, Australia, United States and Canada. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: "With the first patient successfully completing the safety evaluation period with IKS03, Iksuda demonstrates its continued commitment to drive its differentiated ADCs through clinical proof of concept, further solidifying our position as a clinical-stage ADC-focused company. Although there have been advances in the treatment of non-Hodgkin lymphoma in recent years, there remains a significant unmet patient need, and we hope that IKS03 will be able to build on the potential benefit-risk profile suggested by the data generated in preclinical studies." About IKS03 IKS03 is a best-in-class CD19-targeting ADC delivering a tumour-activated prodrug pyrrolobenzodiazepine (PBD) which was licensed from LigaChem Biosciences (formerly LegoChem Biosciences) ( Preclinical testing demonstrates best-in-class efficacy (vs in-clinic and marketed CD19-targeted therapies) in in vivo xenograft models and significantly raised maximum tolerated dose (MTD) in non-human primate disease models, demonstrating its potential to be the leading anti-CD19 therapy in B-cell cancers. About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on Contacts For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive OfficerTel: +44 (0) 191 6031680Email info@ FTI Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy ByrneTel: +44 (0) 020 3727 1000Iksuda@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ('Zenas' or the 'Company') (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management's presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under 'Events and Presentations' in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas' lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab's unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit and follow us on LinkedIn. The Zenas BioPharma word mark, logo mark, and the 'lightning bolt' design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved. Investor and Media Contact:Argot PartnersZenas@
Associated Press
31-03-2025
- Business
- Associated Press
Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer
-- Dr. Bolen has an established track record advancing disruptive medicines from the clinic through approval -- WATERTOWN, Mass., March 31, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat oncology and autoimmune diseases, today announced the appointment of Joseph Bolen, Ph.D., as Chief Executive Officer. Dr. Bolen most recently served as Orna's Chief Scientific Officer (CSO) and succeeds Amit Munshi who is stepping aside for personal reasons. Orna expects to initiate clinical studies in 2026 for its two wholly owned, potentially best-in-class in vivo panCAR assets, including its CD19 program for B cell-driven autoimmune diseases and a BCMA program for multiple myeloma. In addition to its wholly owned pipeline, Orna has secured two major, potentially multi-billion-dollar pharma partnerships with Merck for the development of vaccines and therapeutics in infectious disease and oncology and with Vertex for next generation approaches to sickle cell disease and transfusion-dependent beta thalassemia. 'At its core, Orna is a science driven organization that has greatly benefited from Joe's breadth and depth of drug development expertise,' said Ansbert Gadicke, M.D., Chairman of Orna and Managing Partner of MPM BioImpact. 'This is the perfect time for Joe to take the helm as Orna advances both its proprietary programs in autoimmune and oncology to the clinic. Joe's scientific expertise and organizational leadership capabilities, in conjunction with the Company's strong cash position, will enable us to achieve key milestones across our wholly owned and partnered programs.' Dr. Gadicke continued, 'Amit leaves Orna in a strong position and we would like to express our deep appreciation for his commitment and contributions.' Dr. Bolen joined Orna through its acquisition of ReNAgade Therapeutics and has served as CSO since November 2024, concurrent to his role as an Entrepreneur Partner at MPM BioImpact. Prior to Orna, Dr. Bolen served in leadership roles at ReNAgade Therapeutics. Previously, he oversaw all aspects of R&D for Moderna Therapeutics as CSO and President of Research and Development. Before Moderna, Dr. Bolen was CSO at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company. Earlier in his career, he held senior R&D positions at Hoechst Marion Roussel, Schering-Plough (DNAX) and Bristol Myers Squibb. Dr. Bolen began his career at the National Institutes of Health (NIH). He earned a Ph.D. in Immunology and conducted his postdoctoral training in molecular virology at Kansas State University Cancer Center. He graduated from the University of Nebraska with a B.S. in Microbiology and Chemistry. 'I am excited to lead our world-class team, as we advance some of the most transformative science I've seen in my 35-year career in this industry. Our leading circular RNA paired with our potentially best-in-class delivery technologies hold the potential to overcome the limitations of existing ex-vivo technologies and deliver large-scale impact to patients across a range of diseases,' said Dr. Bolen. 'With robust data in hand demonstrating our ability to deliver and engineer immune cells in vivo, our focus is now on advancing our first two panCAR programs into the clinic in 2026 and continuing to progress our pharma partnerships. I look forward to leading our team through this next exciting chapter of the Company's growth as we unlock the potential of RNA medicines.' About Orna Therapeutics Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA®) therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's circular RNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based delivery systems and comprehensive editing programs position Orna to advance novel RNA medicines with vast potential to transform patient care. To learn more, visit and follow Orna Therapeutics on X and LinkedIn.
Associated Press
25-03-2025
- Business
- Associated Press
CDR-Life Demonstrates Commitment to Differentiated Pipeline with New Autoimmune Candidate CDR111
CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along with upcoming posters highlighting the company's T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, Illinois. Portfolio Expansion: CDR111 CDR111, CDR-Life's newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and CD3, designed to achieve immune reset through broad B cell depletion. This novel therapeutic approach represents a significant expansion of the company's product portfolio beyond oncology into autoimmune diseases, with potential applications across multiple autoimmune conditions. CDR111, CDR-Life's newest clinical candidate, is a trispecific molecule targeting CD19, BCMA and CD3, designed to achieve immune reset through broad B cell depletion. This novel therapeutic approach represents a significant expansion of the company's product portfolio beyond oncology into autoimmune diseases, with potential applications across multiple autoimmune conditions. 'The expansion of our portfolio with CDR111, our newest clinical candidate for autoimmune diseases, marks a significant milestone in our company's growth strategy,' said Christian Leisner, PhD, Chief Executive Officer of CDR-Life. 'This addition, along with data on our advancing oncology programs being presented at AACR, demonstrates the ability of our M-gager® platform to deliver unique and differentiated therapeutic candidates across multiple disease areas.' AACR Poster Presentation Details Title: A novel T cell engager antibody for the treatment of HLA-A*01/KK-LC-1-positive tumors Poster and Abstract Number: Poster Section 38, Poster Board 1; Abstract Number: 3493 Date/Time: Monday, April 28, 2025; 2-5 pm Presenter: Melissa Vrohlings, Head of Translational Science, CDR-Life Title: Durable and potent in vitro T cell activity with repeated exposure to CDR404, a potential best-in-class T cell engager targeting MAGE-A4 Poster and Abstract Number: Poster Section 38, Poster 2; Abstract 3494 Date/Time: Monday, April 28, 2025, 2-5 pm Presenter: Melissa Vrohlings, Head of Translational Science, CDR-Life About CDR-Life CDR-Life develops highly targeted T cell engagers (TCEs) for the treatment of solid cancers and autoimmune diseases. Our M-gager® platform delivers TCEs against challenging intracellular and surface antigens through unparalleled target-specificity. With our first oncology program now in clinical trials, we are advancing a pipeline of potent and selective TCE therapeutics. Our partnership with Boehringer Ingelheim on a molecule derived from our M-gager® platform, progressing to Phase 2 trials, demonstrates the potential of our antibody-derived molecules. Backed by leading cross-Atlantic investors, our team is committed to bringing life-changing, disease-modifying medicines to patients globally. Learn more at . Lauren Arnold LA Communications [email protected]: CDR-Life Inc. SOURCE: CDR-Life Copyright Business Wire 2025. PUB: 03/25/2025 04:45 PM/DISC: 03/25/2025 04:45 PM
Yahoo
05-02-2025
- Business
- Yahoo
CAR T-Cell Therapy Market Forecasts to 2035, with Competitor Profiles of Autolus, Bluebird Bio, Carsgen Therapeutics, Cellectis, Noile-Immune Biotech, Shanghai GeneChem, Takara Bio and More
Close to 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research activity. At present, over 230 companies are engaged in the development of CAR T-cell therapies for the treatment of different oncological, non-oncological and other disorders. CAR T-Cell Therapy Patent CAR T-Cell Therapy Pipeline Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035" report has been added to offering. The global CAR T-cell therapy market is estimated to grow from USD 4.6 billion in the current year to USD 15.2 billion by 2035, at a CAGR of 11.4% during the forecast period, till 2035. CAR T-CELL THERAPY MARKET GROWTH AND TRENDS Cancer research continues to be one of the most active segments, in terms of drug development, within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity, drug developers are actively investigating more targeted anti-cancer therapies. Of these, CAR T-cell therapies have emerged as a promising option. CAR T-cell therapy leverages the body's own immune system to target and eliminate cancer cells. CAR-T cell therapies have been demonstrated to enable complete disease remission, omitting the need for additional treatment; several studies have proven the efficacy of these therapy candidates. It is worth highlighting that close to 1,000 clinical trials related to CAR-T cell therapies have been registered in the past eight years, indicating substantial research activity. At present, over 230 companies are engaged in the development of CAR T-cell therapies for the treatment of different oncological, non-oncological and other disorders. Along with the technological advancements in molecular research, the surge in demand for personalized cancer treatment and increase in the number of clinical trials and multiple therapy approvals are some other considerable factors, aiding the growth of this market. Furthermore, continuous financial support from investors is expected to propel the steady growth for the development of CAR-T cell therapy in the mid to long-term. CAR T-CELL THERAPY MARKET KEY INSIGHTS The report delves into the current state of the CAR T-cell therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include: CAR-T cell therapies, with over 1240 preclinical / clinical product candidates, represent one of the most active segments in the pharmaceutical domain. Close to 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; notably, CD19 and BCMA have emerged as the most popular target antigens. Extensive efforts are underway to improve CAR constructs across successive generations, involving alterations in the scFv region via using different types of gene delivery vectors. Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development. In the last eight years, over 970 clinical trials have been registered across different geographies for CAR-T cell therapies; extensive efforts are underway to improve successive generations of these therapies. 375+ scientists from renowned universities are presently involved in the clinical development of CAR-T cell therapies; these KOLs are primarily based in the US and China. The rise in partnerships, in the recent past, involving both international and indigenous stakeholders, validate the growing interest in this domain. Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested more than USD 32 billion, across 370+ instances. More than 11,900 patents related to CAR-T cell therapies have been filed / granted to protect the intellectual property generated within this field. In order to efficiently promote these therapies and sustain their position in the CAR-T cell therapies market, drug developers are actively exploring diverse promotional strategies. Considering the growing prevalence of cancer, technological developments and ongoing approvals, the market for CAR-T cell therapies is poised to witness a steady growth in the foreseen future. With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of over 10%, during the next decade. CAR T-CELL THERAPY MARKET: KEY SEGMENTSMultiple Myeloma is Likely to Dominate the CAR T-Cell Therapy Market During the Forecast Period Based on target indication, the market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, large B-cell lymphoma, mantle cell lymphoma, multiple myeloma and others. It is worth highlighting that the market for CAR-T therapies designed to treat large B-cell lymphoma is projected to grow at an annual growth rate of 14%, during the forecast period. CD19 Targeting Therapies is Expected to Capture Largest Share in the CAR T-Cell Therapy Market During the Forecast Period Based on target antigen, the market is segmented into CD19, BCMA, CD20, CD19 / CD22 and others. It is worth highlighting that the segment for CD19 is likely to capture more than 65% of the overall market in the coming years. This can be attributed to the success of CD19 targeting therapies, such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). Key Players in the CAR T-Cell Therapy Market Profiled in the Report: Autolus Bluebird Bio Bristol Myers Squibb Carsgen Therapeutics Cellectis, Gilead Sciences Innovative Cellular Therapeutics Noile-Immune Biotech Novartis Shanghai GeneChem Sinobioway Cell Therapy Takara Bio Wellington Zhaotai Therapies KEY QUESTIONS ANSWERED IN THIS REPORT How many companies are currently engaged in this market? Which are the leading companies in this market? What kind of partnership models are commonly adopted by industry stakeholders? How many clinical trials are running for CAR-T therapies? What are the factors that are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. ADDITIONAL BENEFITS Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team Free Updated report if the report is 6-12 months old or older Key Topics Covered: 1. PREFACE 2. RESEARCH METHODOLOGY 3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS 4. EXECUTIVE SUMMARY5. INTRODUCTION5.1. Chapter Overview5.2. Overview of T-cell Immunotherapies5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy 6. CAR-T CELL THERAPIES: MARKET LANDSCAPE6.1. Chapter Overview6.2. CAR-T Cell Therapies: Market Landscape6.3. CAR-T Cell Therapies: Overall Developer Landscape 7. KEY INSIGHTS7.1. Chapter Overview7.2. CAR-T Cell Therapies: Popular Target Antigens7.3. CAR-T Therapies: CAR Construct Analysis 8. CLINICAL TRIAL ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. CAR-T Cell Therapies: Clinical Trial Analysis 9. KEY OPINION LEADERS9.1. Chapter Overview9.2. Assumptions and Key Parameters9.3. Methodology9.4. CAR-T Cell Therapies: Key Opinion Leaders 10. COMPANY PROFILES Autolus Bluebird Bio Bristol Myers Squibb CARsgen Therapeutics Cellectis Gilead Sciences Innovative Cellular Therapeutics Noile-Immune Biotech Novartis Sinobioway Cell Therapy Takara Bio Wellington Zhaotai Therapies 11. PARTNERSHIPS AND COLLABORATIONS11.1. Chapter Overview11.2. Partnership Models11.3. CAR-T Cell Therapies: Partnerships and Collaborations 12. FUNDING AND INVESTMENTS ANALYSIS12.1. Chapter Overview12.2. Types of Funding12.3. CAR-T Cell Therapies: Funding and Investment Analysis 13. PATENT ANALYSIS13.1. Chapter Overview13.2. Scope and Methodology13.3. CAR-T Cell Therapies: Patent Analysis13.4. Patent Benchmarking Analysis13.5. Patent Valuation13.6. Leading Patents by Number Of Citations 14. CASE STUDY: CELL THERAPY MANUFACTURING14.1. Chapter Overview14.2. Overview of Cell Therapy Manufacturing14.3. Cell Therapy Manufacturing Models14.4. Scalability of Cell Therapy Manufacturing Processes14.5. Types of Cell Therapy Manufacturers14.6. Key Challenges Related to Manufacturing of Cell Therapies14.7. Key Considerations for Cell Therapy Manufacturing14.8. Automation of Cell Therapy Manufacturing Process14.9. Cell Therapy Manufacturing Supply Chain14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers14.11. Regulatory Landscape14.12. Future Perspectives 15. COST PRICE ANALYSIS15.1. Chapter Overview15.2. Factors Contributing to the High Price of Cell / Gene Therapies15.3. Pricing Models for T-cell Immunotherapies15.4. Reimbursement related Considerations for T-cell Immunotherapies15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies 16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 17. GLOBAL CAR-T CELL THERAPY MARKET17.1. Chapter Overview17.2. Key Assumptions and Methodology17.3. Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Future Estimates (till 2035)17.4. Scenario Analysis17.5. Key Market Segmentations 18. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN18.1. Chapter Overview18.2. Key Assumptions and Methodology18.3. CAR-T Cell Therapies Market: Distribution by Type Target Antigen, Current Year and 2035 19. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION19.1. Chapter Overview19.2. Key Assumptions and Methodology19.3. CAR-T Cell Therapies Market: Distribution by Target Indication, Current Year and 2035 20. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS20.1. Chapter Overview20.2. Key Assumptions and Methodology20.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, Current Year and 2035 21. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS21.1. Chapter Overview21.2. Key Assumptions and Methodology21.3. Commercialized CAR-T Cell Therapies: Sales Forecast Kymriah (Tisagenlecleucel-T) Yescarta (axicabtagene ciloleucel) Tecartus (Brexucabtagene Autoleucel) Abecma (Idecabtagene Vicleucel / bb211211) CARVYKTI (LCAR-B38M CAR-T / JNJ-6821845218 / Ciltacabtagene Autoleucel) BREYANZI (Lisocabtagene maraleucel, JCAR017) Carteyva (Relmacabtagene autoleucel / JWCAR0219) NexCART Fucaso (Equecabtagene Autoleucel) Inaticabtagene Autoleucel CNCT19 / HY001 Zevorcabtagene autoleucel (CT053) 21.4. Clinical CAR-T Cell Therapies: Sales Forecast CAR-BCMA T cells CAR-T-CD19 Cells Descartes-08 Zamtocabtagene Autoleucel (MB-CART21019.1) CAR-T ddBCMA CRG-02121 cells CT041 ALLO-501A / ALLO-501 ALLO-605 Descartes-25 AUTO1 AUTO3 (CD19/2121 CAR-T) AUTO4 (CD19/2121 CAR-T) CD19-CAR-T Humanized CD19-CAR-T IM19 CAR-T CCT301 CAR-T CARCIK-CD19 CD123 CAR-T cells BCMA CAR-T CD19/CD22-CAR-T GC012F (Dual CAR-BCMA- 19) CD19/CD210-CART CD7 CAR-T Anti-FLT3 CAR-T / TAA05 Anti-ALPP CAR-T Cells WU CART 007 CTX110 TX2100-TR101 ALETA-001 PBCAR0191 22. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS22.1. Chapter Overview22.2. Key Assumptions and Methodology22.3. CAR-T Cell Therapies: Leading Players Sales Forecasts Gilead Sciences Bristol Myers Squibb Novartis Janssen JW Therapeutics 23. PROMOTIONAL ANALYSIS23.1. Chapter Overview23.2. Channels Used for Promotional Campaigns23.3. Summary of Product Website Analysis23.4. Summary of Patient Support Services and Informative Downloads Kymriah: Promotional Analysis Yescarta: Promotional Analysis Tecartus: Promotional Analysis Breyanzi: Promotional Analysis Abecma: Promotional Analysis Carvykti: Promotional Analysis 24. EXECUTIVE INSIGHTS Atara Biotherpeutics Glycostem Therapeutics Gracell Biotechnologies TxCell Kite Pharma Celyad Waisman Biomanufacturing Theravectys Changhai Hospital For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachments CAR T-Cell Therapy Patent CAR T-Cell Therapy Pipeline CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
